Monkeypox vaccine highly effective, US data show

Monkey pox vaccine highly effective, show improved data ricans

BET À DAY

The monkeypox vaccine is highly effective as early as two weeks after the first dose, according to initial real-world data released by US health authorities on Wednesday. < /p>

Unvaccinated people are 14 times more likely to be infected with monkeypox than those vaccinated, according to the Centers for Disease Control and Prevention (CDC), the nation's top federal health agency .

This analysis was conducted by comparing the number of confirmed cases in vaccinated and unvaccinated people, within the eligible population (people at risk, including men who have sex with men). The analysis includes data from around 30 US states, between July and September 2022.

The vaccine from the Bavarian Nordic laboratory, marketed under the name Jynneos in the United States, is the only one approved specifically against monkeypox.

It is administered in two doses, 28 days apart l each other. But the CDC data took into account the cases of people who had so far only received a single dose (at least two weeks previously). They therefore suggest that the vaccine already offers some protection from the first dose.

Two doses recommended 

Authorities plan to collect efficacy data after the second dose as well, and continue to recommend these two doses for maximum protection.

“We have only limited performance data so far. of the vaccine against monkeypox in real conditions”, underlined during a press conference Rochelle Walensky, the director of the CDC. “These new data allow us to be cautiously optimistic that the vaccine is working as expected.”

The Jynneos vaccine had been approved based on animal and human studies evaluating the immune reaction caused by its injection, but not on measures of its effectiveness.

Nearly 700,000 doses of this vaccine have been administered in the United States, which has recorded more than 25,000 cases of monkeypox since May. After a peak in daily infections in mid-August, the rate of new infections has slowed.

More than 66,000 cases have been recorded worldwide in 2022, the vast majority outside countries from Africa where the disease is endemic.